Antimicrobial Drug Reviews Would Need To Consider “Resistance” Under Bill
Executive Summary
Impact on drug-resistant microbes would be a factor considered during the review of antimicrobial drug applications under legislation introduced in the House Sept. 27 by Reps. Jim Matheson, D-Utah, and Mike Ferguson, R-N.J
You may also be interested in...
Antibiotic Resistance Gets Attention Of FDA, Congress
Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.
Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
Overuse of antibiotics could be controlled using elements of FDA’s Risk Evaluation and Mitigation Strategies, the Infectious Diseases Society of America argues in an upcoming position paper.
Antibiotics Need REMS For Public, Not Patient, Safety Reasons, IDSA Says
Overuse of antibiotics could be controlled using elements of FDA’s Risk Evaluation and Mitigation Strategies, the Infectious Diseases Society of America argues in an upcoming position paper.